Physician profile
Victor Lin
NPI 1548614449
$406.51
in general payments reported to CMS, 2019-2025
12 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $406.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $74.57 | 2025 | |
| Lilly USA, LLC | $57.90 | 2025 | Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $47.32 | 2025 | Aptima |
| Novo Nordisk INC | $43.89 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $36.71 | 2025 | Breztri |
| Verity Pharmaceuticals INC. | $33.20 | 2025 | Tlando |
| Viiv Healthcare Company | $28.98 | 2025 | Dovato |
| Shield Therapeutics INC | $24.47 | 2025 | |
| Glaxosmithkline, LLC. | $23.02 | 2025 | Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.17 | 2025 | Xifaxan |
| Organon LLC | $14.28 | 2025 | Nexplanon |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.